drugset
drugset / Trial / NCT00619385

A Safety and Pharmacokinetic Study of Proellex®

NCT00619385 ↗

Phase 1 Completed 25 enrolled Repros Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Dose escalating study of 7 daily doses of Proellex at 100 mg, 150 mg and 200 mg

Timeline

Start
2008-02
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Proellex Other / unclassified 100 mg —
Subject Proellex Other / unclassified 150 mg —
Subject Proellex Other / unclassified 200 mg —

Indications

No indication recorded.